Decision Diagnostics Corp (DECN)

[Leirum]

The quarterly will be submitted late.
A fact is their product is under review with the FDA.


Here from the last 10Q filing from March 31sth under Management Discussions, where it says:

In anticipation of the introduction of Genstrip, which is subject to FDA approval, and currently in that approval
process, we have phased out sales of those brand name products that have been a backbone of our current distribution business but
will, in the future, would compete directly with our Shasta Genstrip. Phasing out these products lowered our order intake by
approximately $8,450,000 in FY2011 and $3,250,000 through the period ending March 31, 2012.